• TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.

  Blee AM, He Y, Yang Y, Ye Z, Yan Y, Pan Y, Ma T, Dugdale J, Kuehn E, Kohli M, Jimenez R, Chen Y, Xu W, Wang L, Huang H.
  Clin Cancer Res. 2018 Sep 15. 18(24).
  
  Data

• Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.

  Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, Schultz N, Taylor B, Vickers A, Cuzick J, Sawyers CL.
  Elife. 2018 Sep 04. (7).

• Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

  Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW.
  Leukemia. 2018 Sep. 9(32).
  
  Clinical Trial

• RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.

  Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG.
  Nat Cell Biol. 2018 Sep. 9(20).
  
  Model Clinical Trial

• Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia.

  Watanabe-Smith K, Druker BJ, Tyner JW, Edwards DK.
  Haematologica. 2018 Aug. 8(103).

• Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.

  Jenkins C, Luty SB, Maxson JE, Eide CA, Abel ML, Togiai C, Nemecek ER, Bottomly D, McWeeney SK, Wilmot B, Loriaux M, Chang BH, Tyner JW.
  Sci Signal. 2018 Jul 17. 539(11).

• Patient derived organoids to model rare prostate cancer phenotypes.

  Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H.
  Nat Commun. 2018 Jun 19. 1(9).
  
  Data Model

• Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.

  Chen Y, Chi P.
  J Hematol Oncol. 2018 Jun 07. 1(11).

• TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.

  Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA.
  J Clin Invest. 2018 Jun 01. 6(128).

• A Convergence-Based Framework for Cancer Drug Resistance.

  Konieczkowski DJ, Johannessen CM, Garraway LA.
  Cancer Cell. 2018 May 14. 5(33).

• Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.

  Zhang H, Coblentz C, Watanabe-Smith K, Means S, Means J, Maxson JE, Tyner JW.
  J Biol Chem. 2018 May 11. 19(293).

• Fasting Activates Fatty Acid Oxidation to Enhance Intestinal Stem Cell Function during Homeostasis and Aging.

  Mihaylova MM, Cheng CW, Cao AQ, Tripathi S, Mana MD, Bauer-Rowe KE, Abu-Remaileh M, Clavain L, Erdemir A, Lewis CA, Freinkman E, Dickey AS, La Spada AR, Huang Y, Bell GW, Deshpande V, Carmeliet P, Katajisto P, Sabatini DM, Yilmaz ÖH.
  Cell Stem Cell. 2018 May 03. 5(22).

• The long tail of oncogenic drivers in prostate cancer.

  Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM, Schultz N, Van Allen EM.
  Nat Genet. 2018 May. 5(50).

• Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

  Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.
  Eur Urol. 2018 May. 5(73).

• COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.

  Xie Y, Cao Z, Wong EW, Guan Y, Ma W, Zhang JQ, Walczak EG, Murphy D, Ran L, Sirota I, Wang S, Shukla S, Gao D, Knott SR, Chang K, Leu J, Wongvipat J, Antonescu CR, Hannon G, Chi P, Chen Y.
  J Clin Invest. 2018 Apr 02. 4(128).

• Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.

  Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, Chen J, Yu Z, He Y, Jin X, Pan Y, Ma T, Wang S, Hou X, Weroha SJ, Karnes RJ, Zhang J, Westendorf JJ, Wang L, Chen Y, Xu W, Zhu R, Wang D, Huang H.
  EMBO Mol Med. 2018 Apr. 4(10).

• Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF^V600E Colorectal Cancer.

  Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB.
  Cancer Discov. 2018 Apr. 4(8).
  
  Data Model

• Challenges in validating candidate therapeutic targets in cancer.

  Settleman J, Sawyers CL, Hunter T.
  Elife. 2018 Feb 08. (7).

• Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia.

  Lamble AJ, Dietz M, Laderas T, McWeeney S, Lind EF.
  J Immunol Methods. 2018 Feb. (453).

• Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

  Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S.
  Cancer Discov. 2018 Feb. 2(8).

• A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.

  Spiciarich DR, Oh ST, Foley A, Hughes SB, Mauro MJ, Abdel-Wahab O, Press RD, Viner R, Thompson SL, Chen Q, Azadi P, Bertozzi CR, Maxson JE.
  Cancer Res. 2018 Dec 15. 24(78).

• Organoid Modeling of the Tumor Immune Microenvironment.

  Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K, Schultz LM, Metzner TJ, Nadauld LD, Tseng YY, Alkhairy S, Oh C, Keskula P, Mendoza-Villanueva D, De La Vega FM, Kunz PL, Liao JC, Leppert JT, Sunwoo JB, Sabatti C, Boehm JS, Hahn WC, Zheng GXY, Davis MM, Kuo CJ.
  Cell. 2018 Dec 13. 7(175).
  
  Data Model

• Two myeloid leukemia cases with rare FLT3 fusions.

  Zhang H, Paliga A, Hobbs E, Moore S, Olson S, Long N, Dao KT, Tyner JW.
  Cold Spring Harb Mol Case Stud. 2018 Dec. 6(4).

• T Helper Cell Cytokines Modulate Intestinal Stem Cell Renewal and Differentiation.

  Biton M, Haber AL, Rogel N, Burgin G, Beyaz S, Schnell A, Ashenberg O, Su CW, Smillie C, Shekhar K, Chen Z, Wu C, Ordovas-Montanes J, Alvarez D, Herbst RH, Zhang M, Tirosh I, Dionne D, Nguyen LT, Xifaras ME, Shalek AK, von Andrian UH, Graham DB, Rozenblatt-Rosen O, Shi HN, Kuchroo V, Yilmaz OH, Regev A, Xavier RJ.
  Cell. 2018 Nov 15. 5(175).

• Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

  Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.
  J Clin Invest. 2018 Nov 01. 11(128).

• Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

  Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.
  Cell. 2018 Nov 01. 4(175).
  
  Data Clinical Trial

• Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.

  Hosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JW, Agarwal A.
  Leukemia. 2018 Nov. 11(32).

• Therapeutic strategies to target RAS-mutant cancers.

  Ryan MB, Corcoran RB.
  Nat Rev Clin Oncol. 2018 Nov. 11(15).

• Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

  Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.
  J Clin Invest. 2018 Oct 01. 10(128).

• Functional genomic landscape of acute myeloid leukaemia.

  Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.
  Nature. 2018 Oct. 7728(562).
  
  Data Clinical Trial

• Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast.

  Siravegna G, Corcoran RB.
  Cancer Discov. 2018 Oct. 10(8).

• Automation of ReactomeFIViz via CyREST API.

  Loney F, Wu G.
  F1000Res. 2018. (7).

• Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.

  Lamble AJ, Lind EF.
  Front Oncol. 2018. (8).

• Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.

  Nanjo S, Bivona TG.
  J Thorac Dis. 2018 Nov. Suppl 33(10).

• Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.

  Singer JW, Fleischman A, Al-Fayoumi S, Mascarenhas JO, Yu Q, Agarwal A.
  Oncotarget. 2018 Sep 07. 70(9).

• Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.

  Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM.
  Oncotarget. 2018 May 15. 37(9).

• Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.

  Zaman A, Bivona TG.
  Ann Transl Med. 2018 May. 9(6).